These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34856572)

  • 1. The Potential Prognostic and Therapeutic Implications of Prolactin Receptor and Growth Hormone-releasing Hormone Receptor Expression in Uterine Leiomyosarcomas.
    Jones TE; La HS; Upadhyay-Baskota S; Bhargava R; Jones MW
    Int J Gynecol Pathol; 2022 Nov; 41(6):566-572. PubMed ID: 34856572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
    Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin receptor expression as a novel prognostic biomarker for triple negative breast cancer patients.
    Motamedi B; Rafiee-Pour HA; Khosravi MR; Kefayat A; Baradaran A; Amjadi E; Goli P
    Ann Diagn Pathol; 2020 Jun; 46():151507. PubMed ID: 32199279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.
    Lusby K; Savannah KB; Demicco EG; Zhang Y; Ghadimi MP; Young ED; Colombo C; Lam R; Dogan TE; Hornick JL; Lazar AJ; Hunt KK; Anderson ML; Creighton CJ; Lev D; Pollock RE
    Ann Surg Oncol; 2013 Jul; 20(7):2364-72. PubMed ID: 23334251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro.
    Langan EA; Ramot Y; Hanning A; Poeggeler B; Bíró T; Gaspar E; Funk W; Griffiths CE; Paus R
    Br J Dermatol; 2010 May; 162(5):1127-31. PubMed ID: 20302576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of prolactin receptor expression in breast cancer subtypes].
    Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
    Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
    Rao UN; Finkelstein SD; Jones MW
    Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
    Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex-related hormone receptor in laryngeal squamous cell carcinoma: correlation with androgen estrogen-ɑ and prolactin receptor expression and influence of prognosis.
    Fei M; Zhang J; Zhou J; Xu Y; Wang J
    Acta Otolaryngol; 2018 Jan; 138(1):66-72. PubMed ID: 28889782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations.
    Haglund F; Lu M; Vukojević V; Nilsson IL; Andreasson A; Džabić M; Bränström R; Höög A; Juhlin CC; Larsson C
    PLoS One; 2012; 7(5):e36448. PubMed ID: 22606260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
    Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
    Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.
    Tantari M; Barra F; Di Domenico S; Ferraioli D; Vellone VG; De Cian F; Ferrero S
    Expert Opin Pharmacother; 2019 Apr; 20(6):713-723. PubMed ID: 30724615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies.
    Ginsburg E; Alexander S; Lieber S; Tarplin S; Jenkins L; Pang L; Heger CD; Goldsmith P; Vonderhaar BK
    BMC Cancer; 2010 Dec; 10():678. PubMed ID: 21144038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine control of canine mammary neoplasms: serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors.
    Spoerri M; Guscetti F; Hartnack S; Boos A; Oei C; Balogh O; Nowaczyk RM; Michel E; Reichler IM; Kowalewski MP
    BMC Vet Res; 2015 Sep; 11():235. PubMed ID: 26370564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck.
    Bauernhofer T; Pichler M; Wieckowski E; Stanson J; Aigelsreiter A; Griesbacher A; Groselj-Strele A; Linecker A; Samonigg H; Langner C; Whiteside TL
    Br J Cancer; 2011 May; 104(10):1641-8. PubMed ID: 21505459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating prolactin and tumoral prolactin receptors in men with tongue cancer: a preliminary study.
    Patel DD; Bhatavdekar JM; Vora HH; Balar DB
    Eur J Surg Oncol; 1994 Apr; 20(2):155-9. PubMed ID: 8181582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connections between prolactin and ovarian cancer.
    Alkharusi A; AlMuslahi A; AlBalushi N; AlAjmi R; AlRawahi S; AlFarqani A; Norstedt G; Zadjali F
    PLoS One; 2021; 16(8):e0255701. PubMed ID: 34358244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
    McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
    Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.